Molecular screening for advanced pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to implement molecular screening for patients with advanced or metastatic pancreatic cancer prior to starting their first line of treatment. By analyzing tumor and blood samples, the study seeks to identify genomic and transcriptomic profiles that can guide personalized medicine approaches. The goal is to better select patients for targeted therapies and combinations with chemotherapy, potentially improving treatment outcomes. The study focuses on patients who have received limited prior systemic chemotherapy and have accessible archival tumor samples.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patient \> 18 years
* metastatic or advanced PDAC
* Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
* Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
* Life expectancy \> 3 months
* PS score 0 or 1.

Exclusion Criteria:

* Curative therapy available
* Any condition contraindicated with blood sampling procedures required by the protocol.
* Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
* Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.

Where it's running

• Centre Léon Bérard
  Lyon, France Recruiting

Study contacts

• Principal investigator: Philippe CASSIER, MD, PhD — Centre Leon Berard
• Study coordinator: Philippe CASSIER, MD, PhD
• Email: philippe.cassier@lyon.unicancer.fr
• Phone: 0426556833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• GKL-006 injections with nab-paclitaxel and gemcitabine for advanced pancreatic cancer

  This study tests GKL-006 given with standard chemotherapy to see if it helps patients with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Beijing Gene Key Life Technology Co., Ltd · Beijing, Beijing Municipality · NCT07777211

• IBI343 with chemotherapy in advanced pancreatic cancer

  This study tests whether IBI343 combined with chemotherapy is safe and can help people with advanced pancreatic cancer.

  Recruiting Phase 1/2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07692750

• Claudin18.2-targeted activated dendritic cell plus CAR-T therapy for advanced pancreatic cancer

  This trial will test whether combining Claudin18.2-targeted activated dendritic cells with Claudin18.2 CAR-T cells helps people with advanced pancreatic cancer whose tumors express Claudin18.2.

  Recruiting Early Phase 1 Hainan Cancer Hospital · Haikou, Hainan · NCT07416240

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• GFH375 plus chemotherapy in KRAS G12D-mutant metastatic pancreatic cancer

  This trial tests GFH375 in combination with standard chemotherapy to see if it helps people with KRAS G12D-mutant metastatic pancreatic cancer who have already been treated fail or progress on prior therapy.

  Recruiting Phase 3 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality · NCT07262567

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.